Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




May
05
Today In Oncology
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
CLL Linked to Increased Skin Cancer Risk and Mortality
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo